Research programme: ICP4 antagonists - Signal

Drug Profile

Research programme: ICP4 antagonists - Signal

Alternative Names: ICP4 antagonists research programme - Signal

Latest Information Update: 07 Nov 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Signal Research Division
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 07 Nov 2003 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 27 Aug 2001 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
  • 07 Sep 2000 Signal Pharmaceuticals has been acquired by Celgene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top